|
CA2336624C
(en)
*
|
1998-07-06 |
2008-10-21 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
|
|
ID29584A
(id)
*
|
1999-02-11 |
2001-09-06 |
Pfizer Prod Inc |
Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
|
|
ATE260269T1
(de)
*
|
1999-11-05 |
2004-03-15 |
Cytovia Inc |
Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
|
|
ES2212971T3
(es)
*
|
1999-11-30 |
2004-08-16 |
Pfizer Products Inc. |
Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
|
|
HN2000000266A
(es)
*
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
|
WO2001054688A1
(en)
*
|
2000-01-28 |
2001-08-02 |
Merck & Co., Inc. |
Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
|
|
JO2361B1
(en)
*
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
|
JP4974438B2
(ja)
*
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
|
|
AU2001293826A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
|
WO2002024683A1
(en)
|
2000-09-25 |
2002-03-28 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
|
|
AU2001293835A1
(en)
*
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
|
EA007464B1
(ru)
*
|
2000-10-02 |
2006-10-27 |
Янссен Фармацевтика Н.В. |
Антагонисты метаботропных рецепторов глутамата
|
|
WO2002042296A1
(en)
|
2000-11-21 |
2002-05-30 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting benzoheterocyclic derivatives
|
|
EP1347966B1
(en)
|
2000-12-27 |
2006-03-08 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
|
DE60119383T2
(de)
*
|
2000-12-27 |
2007-04-19 |
Janssen Pharmaceutica N.V. |
Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
|
|
WO2002092594A1
(en)
*
|
2001-05-16 |
2002-11-21 |
Cytovia, Inc. |
Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
WO2002092076A1
(en)
*
|
2001-05-16 |
2002-11-21 |
Cytovia, Inc. |
Substituted coumarins and quinolines as caspases activators
|
|
US6858607B1
(en)
|
2001-05-16 |
2005-02-22 |
Cytovia, Inc. |
7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
WO2003006006A1
(en)
*
|
2001-07-09 |
2003-01-23 |
The Regents Of The University Of California |
Use of matrix metalloproteinase inhibitors to mitigate nerve damage
|
|
CA2469275C
(en)
|
2001-12-19 |
2011-09-06 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
|
ATE364384T1
(de)
*
|
2002-03-22 |
2007-07-15 |
Janssen Pharmaceutica Nv |
Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
|
|
PL218788B1
(pl)
*
|
2002-03-29 |
2015-01-30 |
Janssen Pharmaceutica Nv |
Znakowane radioaktywnie pochodne chinoliny i jej zastosowanie
|
|
ATE336496T1
(de)
|
2002-04-15 |
2006-09-15 |
Janssen Pharmaceutica Nv |
Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
|
|
EP1509515A4
(en)
|
2002-05-16 |
2006-07-05 |
Cytovia Inc |
SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE
|
|
AU2003241482A1
(en)
|
2002-05-16 |
2003-12-02 |
Cytovia, Inc. |
Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
|
BR0317548A
(pt)
*
|
2002-12-19 |
2005-11-22 |
Pfizer |
Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
|
|
DK1603570T5
(da)
|
2003-02-26 |
2013-12-09 |
Sugen Inc |
Aminoheteroarylforbindelser som proteinkinaseinhibitorer
|
|
TW200504057A
(en)
*
|
2003-02-27 |
2005-02-01 |
Chugai Pharmaceutical Co Ltd |
Benzothiophene derivative
|
|
AU2004259755A1
(en)
*
|
2003-07-22 |
2005-02-03 |
Janssen Pharmaceutica, N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
EP1691812A4
(en)
|
2003-11-20 |
2010-01-13 |
Childrens Hosp Medical Center |
GTPASE INHIBITORS AND METHOD OF USE
|
|
EP1744751A4
(en)
*
|
2004-03-18 |
2010-03-10 |
Brigham & Womens Hospital |
METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
JP2007529555A
(ja)
*
|
2004-03-18 |
2007-10-25 |
ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド |
シヌクレイノパチーを治療する方法
|
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
|
US20060106060A1
(en)
*
|
2004-03-18 |
2006-05-18 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
|
JP2007530654A
(ja)
*
|
2004-03-30 |
2007-11-01 |
ファイザー・プロダクツ・インク |
シグナル伝達阻害剤の組合せ
|
|
MX2007001986A
(es)
*
|
2004-08-26 |
2007-05-10 |
Pfizer |
Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
|
|
JP4242911B2
(ja)
|
2004-08-26 |
2009-03-25 |
ファイザー・インク |
プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
|
|
CA2577937C
(en)
*
|
2004-08-26 |
2010-12-21 |
Pfizer Inc. |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
|
WO2006041900A2
(en)
*
|
2004-10-07 |
2006-04-20 |
Cytovia, Inc. |
SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
|
|
US7826982B2
(en)
|
2005-07-29 |
2010-11-02 |
Children's Hospital Medical Center |
Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
|
|
DK1933871T3
(da)
|
2005-09-07 |
2013-07-08 |
Amgen Fremont Inc |
Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
|
|
AU2006292278B2
(en)
|
2005-09-20 |
2012-03-08 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
JP2009521470A
(ja)
*
|
2005-12-23 |
2009-06-04 |
リンク メディシン コーポレイション |
シヌクレイン障害の治療
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
EP2258700A1
(en)
|
2006-05-09 |
2010-12-08 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
|
MY150756A
(en)
|
2006-08-21 |
2014-02-28 |
Hoffmann La Roche |
Tumor theraphy with an anti-vegf antibody
|
|
JP5492075B2
(ja)
*
|
2007-05-23 |
2014-05-14 |
アラーガン インコーポレイテッド |
アドレナリンレセプター作用薬としての（（二環式ヘテロアリール）イミダゾリル）メチルヘテロアリール化合物
|
|
CA2688897A1
(en)
*
|
2007-05-23 |
2008-11-23 |
Allergan, Inc. |
Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
|
|
US8129356B2
(en)
*
|
2007-10-01 |
2012-03-06 |
Vanderbilt University |
Bmx mediated signal transduction in irradiated vascular endothelium
|
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
|
WO2010057006A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Link Medicine Corporation |
Azaquinolinone derivatives and uses thereof
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
EP2393814A1
(en)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
|
PE20151203A1
(es)
|
2012-10-16 |
2015-08-31 |
Janssen Pharmaceutica Nv |
MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
|
|
PE20150778A1
(es)
|
2012-10-16 |
2015-05-23 |
Janssen Pharmaceutica Nv |
Moduladores de quinolinilo unidos a metileno de ror-gamma-t
|
|
KR20150070348A
(ko)
|
2012-10-16 |
2015-06-24 |
얀센 파마슈티카 엔.브이. |
RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
DK2970205T3
(da)
|
2013-03-14 |
2019-07-29 |
Tolero Pharmaceuticals Inc |
JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
US9624225B2
(en)
|
2013-10-15 |
2017-04-18 |
Janssen Pharmaceutica Nv |
Quinolinyl modulators of RORγt
|
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
|
US9346782B2
(en)
|
2013-10-15 |
2016-05-24 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
|
US20180371551A1
(en)
|
2015-12-03 |
2018-12-27 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
|
CN108003150A
(zh)
*
|
2016-10-31 |
2018-05-08 |
河南工业大学 |
4-杂芳基喹啉酮衍生物的制备方法及其应用
|
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
EP4461315A3
(en)
|
2019-08-16 |
2025-03-05 |
Children's Hospital Medical Center |
Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|